NYSE$PBH

Prestige Consumer Healthcare Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Briefing

Prestige Consumer Healthcare reported Q4 fiscal 2025 net sales of $296.5M with net income of $50.1M and diluted EPS of $1.01.

Net sales were $296.5 million for the quarter ended March 31, 2025. Net income was $50.1 million; diluted EPS was $1.01 (adjusted $1.32). OTC brands in women's health, GI, and eye care anchor cash flows.

  • Q4 net sales $296.5M.
  • Net income $50.1M; diluted EPS $1.01 (adj. $1.32).
  • Brand portfolio and pricing power in OTC categories.
  • Input costs and retailer inventory affect quarterly trends.

Headline financials

Total Revenue

$297M

Previous: $277M+7.0%
EPS (adj)

$1.32

Previous: $1.02+29.4%
Net Debt

$900M

No prior period
Leverage Ratio

2.4

No prior period
Net Income

$50.1M

Previous: $49.5M+1.4%
Operating Income

$88.4M

Previous: $82.2M+7.6%
Gross Profit

$170M

Previous: $146M+16.3%

Revenue & EPS history

Prestige Consumer · Revenue · Quarterly

$297M

Q4 2025+7%vs Q4 2024
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

Prestige Consumer · $286M total across 2 segments · Q2 2024

  • North American OTC Healthcare
    $244M-3.0%
  • International OTC Healthcare
    $41.9M+12.6%

Forward guidance

Consumer and beverage outlook depends on pricing, volumes, and promotional activity.

Tailwinds

  • Brand strength and innovation pipeline.
  • Cost productivity and mix improvements.

Headwinds

  • Input inflation and private-label competition.
  • Retail inventory and macro discretionary trends.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+1.3%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.3%

Avg return

30 days after

55%

35 / 64 earnings

Positive

+25.7%

Q4 2018

Best reaction

-14.3%

Q3 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+1.5%-7.4%-4.9%
Q3 2026-2.2%-1.4%+0.2%
Q2 2026+2.2%+1.3%+1.7%
Q4 2025+7.0%+6.8%+4.5%
Q3 2025+14.8%+13.0%+17.0%
Q2 2025+3.5%+5.1%+8.6%
Q1 2025-2.4%-0.9%+9.5%
Q4 2024-5.7%-8.3%-8.0%
Q3 2024+9.2%+5.8%+17.2%
Q2 2024+0.1%+0.6%-1.5%
Q1 2024+2.2%-2.5%-11.4%
Q4 2023-0.8%-4.7%-4.5%
Q3 2023-7.9%-8.3%-8.9%
Q2 2023+2.2%+4.6%+17.7%
Q1 2023-0.3%-3.9%-15.2%
Q4 2022-0.8%+4.0%+1.6%
Q3 2022-0.2%+2.2%+1.1%
Q2 2022+2.5%+1.9%-6.0%
Q1 2022+10.5%+12.3%+8.1%
Q4 2021+4.0%+6.2%+12.8%
Q3 2021+3.2%+5.5%+6.3%
Q2 2021-3.5%+3.0%+6.9%
Q1 2021+2.7%-1.9%-5.2%
Q4 2020+1.7%+0.1%+3.5%
Q3 2020+10.7%+5.7%-8.3%
Q2 2020+5.8%+8.5%+8.2%
Q1 2020-3.1%-5.6%-7.9%
Q4 2019+3.8%+1.1%+0.5%
Q3 2019-2.9%+2.8%-4.1%
Q2 2019+4.3%+12.2%+7.4%
Q1 2019+3.5%+5.3%+9.3%
Q4 2018+25.7%+21.4%+25.1%
Q3 2018-14.3%-10.9%-15.3%
Q2 2018-8.3%-9.3%-4.9%
Q1 2018+1.6%+0.7%-2.4%
Q4 2017-8.3%-11.2%-9.5%
Q3 2017+5.8%+4.9%+7.8%
Q2 2017-0.5%+0.8%+0.6%
Q1 2017-1.6%-5.0%-8.1%
Q4 2016-0.7%
Q3 2016+7.6%
Q2 2016-1.7%
Q1 2016-0.2%
Q4 2015+3.3%
Q3 2015+12.5%
Q2 2015-7.6%
Q1 2015+10.1%
Q4 2014+0.2%
Q3 2014-5.5%
Q2 2014+13.2%
Q1 2014+3.3%
Q4 2013-0.4%
Q3 2013+5.8%
Q2 2013+19.9%
Q1 2013+4.1%
Q4 2010+1.4%
Q4 2012+1.4%
Q3 2012-1.0%
Q3 2011-1.0%
Q2 2011-4.8%
Q2 2012-4.8%
Q4 2011-13.0%
Q1 2011-13.0%
Q1 2012-13.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro